NOVANTA INC 8-K
PositiveDeal completedDebt financing
Riverpoint Medical acquisition closes for ≈$1.2B cash plus a $250M milestone payment, expected to double recurring medical consumables revenue.
Filed 2026-07-27 08:15 ET
- 2.01 Completion of Acquisition or Disposition
- 2.03 Creation of a Financial Obligation
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements and Exhibits
Summary
Riverpoint Medical acquisition completed on 7/23/2026. The surgical consumables business is expected to double Novanta’s recurring medical consumables revenue to ≈$300M and increase medical end-market exposure to 60%; Novanta expects immediate accretion to organic growth, adjusted gross margins, adjusted EBITDA growth and margins, and cash flows.
Key Figures
- Purchase consideration: ≈$1.2B in cash at closing, subject to customary adjustments, plus a $250M milestone payment due on or before 1/8/2027.
- Financing: $616M borrowed on 7/22/2026 under the revolving credit and delayed draw term loan facilities; the remaining consideration was funded with cash on hand. Consolidated debt totaled $854.7M as of 7/22/2026. The borrowings mature in June 2030 and may be repaid early without penalty.
- Riverpoint is expected to expand Novanta’s addressable market by $2B. The acquisition is expected to generate a high-single-digit return on invested capital by year three and meet Novanta’s return hurdle by year five.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Adjusted diluted EPS contribution | 2027 | $0.18-$0.25 | — | — |
| Return on invested capital | By year 3 | High single-digit | — | — |
| Return on invested capital | By year 5 | Company’s return hurdle rate | — | — |
Investor Takeaways
- Novanta said it will provide additional detail on Riverpoint’s impact on 2026 financials during its upcoming Q2 earnings call.
The summary is written by an AI model reading the filing.
Model 005 · prompt 5998ea898f · 2026-10-16 20:30:44Z